Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first-in-human

EU flag

European Commission approves Amicus Therapeutics’ Pompe disease therapy

The company can now offer Opfolda together with its previously-approved Pombiliti

Katherine Tupper and Holly Joscelyne's top takeaways from the Patients as Partners conference 2023

Patients as Partners – putting people first in clinical trials

Cuttsy+Cuttsy's key takeaways from the Patients as Partners conference 2023

Cuttsy + Cuttsy

Pride Month 2023 – Innovative Trials

Innnovative Trials' Equality & Diversity committee celebrates Pride Month

Innovative Trials

[Free Whitepaper] 5 Principles for Greater Diversity in Patient Recruitment

Discover how community engagement could enhance diversity in clinical trials patient recruitment

Innovative Trials

- PMLiVE

Innovative Trials attended the Inspire Hertfordshire Award gala dinner

Innovative Trials, a global clinical trial patient recruitment and retention company based in Hertfordshire, has been recognised for its contribution to the county’s economy and business reputation.

Innovative Trials

EU flag

European Commission grants two new marketing authorisations for UCB’s Bimzelx

The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

Navigating patients step by step on their clinical trial journey

For clinical trial participants, navigating their way through a study can sometimes seem daunting and complicated. Without the right support, around 30% are likely to drop out [1], resulting in...

Innovative Trials

- PMLiVE

Innovative Trials responds to national recommendations to tackle UK clinical trial decline

Kate Shaw, Founder & CEO, comments on the Lord report of the Lord O’Shaughnessy review into commercial clinical trials in the UK.

Innovative Trials

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Janssen’s Akeega receives EC approval for metastatic prostate cancer

The authorisation marks the first worldwide approval of the niraparib-based combination

- PMLiVE

Incyte’s Opzelura cream receives EC approval for non-segmental vitiligo

The decision makes Opzelura the first approved treatment in the EU to address repigmentation in this patient population

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links